144 related articles for article (PubMed ID: 23877794)
1. Role of cysteine 288 in nucleophosmin cytoplasmic mutations: sensitization to toxicity induced by arsenic trioxide and bortezomib.
Huang M; Thomas D; Li MX; Feng W; Chan SM; Majeti R; Mitchell BS
Leukemia; 2013 Oct; 27(10):1970-80. PubMed ID: 23877794
[TBL] [Abstract][Full Text] [Related]
2. Arsenic trioxide and proteasome inhibitor bortezomib synergistically induce apoptosis in leukemic cells: the role of protein kinase Cdelta.
Yan H; Wang YC; Li D; Wang Y; Liu W; Wu YL; Chen GQ
Leukemia; 2007 Jul; 21(7):1488-95. PubMed ID: 17495969
[TBL] [Abstract][Full Text] [Related]
3. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
Pei XY; Dai Y; Grant S
Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
[TBL] [Abstract][Full Text] [Related]
4. Synergistic antiproliferative effect of arsenic trioxide combined with bortezomib in HL60 cell line and primary blasts from patients affected by myeloproliferative disorders.
Canestraro M; Galimberti S; Savli H; Palumbo GA; Tibullo D; Nagy B; Guerrini F; Piaggi S; Cine N; Metelli MR; Petrini M
Cancer Genet Cytogenet; 2010 Jun; 199(2):110-20. PubMed ID: 20471514
[TBL] [Abstract][Full Text] [Related]
5. Imidazoquinoxaline derivative EAPB0503: A promising drug targeting mutant nucleophosmin 1 in acute myeloid leukemia.
Nabbouh AI; Hleihel RS; Saliba JL; Karam MM; Hamie MH; Wu HJM; Berthier CP; Tawil NM; Bonnet PA; Deleuze-Masquefa C; El Hajj HA
Cancer; 2017 May; 123(9):1662-1673. PubMed ID: 28055106
[TBL] [Abstract][Full Text] [Related]
6. Selective Toxicity of Investigational Ixazomib for Human Leukemia Cells Expressing Mutant Cytoplasmic NPM1: Role of Reactive Oxygen Species.
Garcia JS; Huang M; Medeiros BC; Mitchell BS
Clin Cancer Res; 2016 Apr; 22(8):1978-88. PubMed ID: 26634271
[TBL] [Abstract][Full Text] [Related]
7. Curcumin stimulates reactive oxygen species production and potentiates apoptosis induction by the antitumor drugs arsenic trioxide and lonidamine in human myeloid leukemia cell lines.
Sánchez Y; Simón GP; Calviño E; de Blas E; Aller P
J Pharmacol Exp Ther; 2010 Oct; 335(1):114-23. PubMed ID: 20605902
[TBL] [Abstract][Full Text] [Related]
8. Arsenic trioxide-induced apoptosis in U937 cells involve generation of reactive oxygen species and inhibition of Akt.
Choi YJ; Park JW; Suh SI; Mun KC; Bae JH; Song DK; Kim SP; Kwon TK
Int J Oncol; 2002 Sep; 21(3):603-10. PubMed ID: 12168106
[TBL] [Abstract][Full Text] [Related]
9. Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells.
Martelli MP; Gionfriddo I; Mezzasoma F; Milano F; Pierangeli S; Mulas F; Pacini R; Tabarrini A; Pettirossi V; Rossi R; Vetro C; Brunetti L; Sportoletti P; Tiacci E; Di Raimondo F; Falini B
Blood; 2015 May; 125(22):3455-65. PubMed ID: 25795919
[TBL] [Abstract][Full Text] [Related]
10. The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide.
Abeltino M; Bonomini S; Bolzoni M; Storti P; Colla S; Todoerti K; Agnelli L; Neri A; Rizzoli V; Giuliani N
Exp Hematol; 2011 Jan; 39(1):55-65. PubMed ID: 20977926
[TBL] [Abstract][Full Text] [Related]
11. Increase sensitivity to chemotherapeutical agents and cytoplasmatic interaction between NPM leukemic mutant and NF-kappaB in AML carrying NPM1 mutations.
Cilloni D; Messa F; Rosso V; Arruga F; Defilippi I; Carturan S; Catalano R; Pautasso M; Panuzzo C; Nicoli P; Messa E; Morotti A; Iacobucci I; Martinelli G; Bracco E; Saglio G
Leukemia; 2008 Jun; 22(6):1234-40. PubMed ID: 18401421
[TBL] [Abstract][Full Text] [Related]
12. Arsenic trioxide induces human pulmonary fibroblast cell death via increasing ROS levels and GSH depletion.
You BR; Park WH
Oncol Rep; 2012 Aug; 28(2):749-57. PubMed ID: 22684917
[TBL] [Abstract][Full Text] [Related]
13. [In vitro effect of bortezomib alone or in combination with harringtonine or arsenic trioxide on proliferation and apoptosis of multidrug resistant leukemia cells].
Cai YX; Meng FY; Sun QX; Fu YB; Li L
Zhonghua Xue Ye Xue Za Zhi; 2008 Nov; 29(11):737-40. PubMed ID: 19176009
[TBL] [Abstract][Full Text] [Related]
14. ASK1 is activated by arsenic trioxide in leukemic cells through accumulation of reactive oxygen species and may play a negative role in induction of apoptosis.
Yan W; Arai A; Aoki M; Ichijo H; Miura O
Biochem Biophys Res Commun; 2007 Apr; 355(4):1038-44. PubMed ID: 17331470
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of panobinostat and marizomib in acute myeloid leukemia and bortezomib-resistant models.
Corrales-Medina FF; Manton CA; Orlowski RZ; Chandra J
Leuk Res; 2015 Mar; 39(3):371-9. PubMed ID: 25612941
[TBL] [Abstract][Full Text] [Related]
16. Effects of arsenic trioxide alone and in combination with bortezomib in multiple myeloma RPMI 8266 cells.
Elmahi AY; Niu C; Li W; Li D; Wang GJ; Hao SS; Cui JW
Asian Pac J Cancer Prev; 2013; 14(11):6469-73. PubMed ID: 24377552
[TBL] [Abstract][Full Text] [Related]
17. [HL-60 cell apoptosis induced by bortezomib alone or in combination with arsenic trioxide in vitro].
Sun QX; Meng FY; Fu YB; Li L; Tian S
Nan Fang Yi Ke Da Xue Xue Bao; 2007 Jul; 27(7):1022-5. PubMed ID: 17666343
[TBL] [Abstract][Full Text] [Related]
18. Role of oxidative stress in the apoptosis of hepatocellular carcinoma induced by combination of arsenic trioxide and ascorbic acid.
Li JJ; Tang Q; Li Y; Hu BR; Ming ZY; Fu Q; Qian JQ; Xiang JZ
Acta Pharmacol Sin; 2006 Aug; 27(8):1078-84. PubMed ID: 16867262
[TBL] [Abstract][Full Text] [Related]
19. [Synergistic effects of arsenic trioxide and proteasome inhibitor bortezomib on apoptosis induction in Raji cell line].
He Y; Yang JM; Wang JM; Zhou H; Lü SQ; Hu XX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Aug; 16(4):794-8. PubMed ID: 18718063
[TBL] [Abstract][Full Text] [Related]
20. Suppression of arsenic trioxide-induced apoptosis in HeLa cells by N-acetylcysteine.
Han YH; Kim SZ; Kim SH; Park WH
Mol Cells; 2008 Jul; 26(1):18-25. PubMed ID: 18511884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
